Literature DB >> 3391862

Pharmacokinetic study of the interaction between rifampicin and ketoconazole.

N Doble1, R Shaw, C Rowland-Hill, M Lush, D W Warnock, E E Keal.   

Abstract

This study assessed the potential pharmacokinetic interaction between rifampicin and ketoconazole, two drugs used to treat the increasingly common combination of Mycobacterium tuberculosis and Candida albicans infection in AIDS patients. The peak plasma rifampicin concentrations in six healthy male subjects were not altered when taken in conjunction with ketoconazole. However, the peak plasma ketoconazole levels were significantly diminished when taken in conjunction with rifampicin, compared to when taken alone (P less than 0.015). The mean area under the curve (AUC) for ketoconazole was significantly diminished when taken with oral or intravenous rifampicin (P less than 0.001).

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3391862     DOI: 10.1093/jac/21.5.633

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  10 in total

Review 1.  Adverse drug reactions to systemic antifungals. Prevention and management.

Authors:  J R Perfect; M H Lindsay; R H Drew
Journal:  Drug Saf       Date:  1992 Sep-Oct       Impact factor: 5.606

Review 2.  Effects of the antifungal agents on oxidative drug metabolism: clinical relevance.

Authors:  K Venkatakrishnan; L L von Moltke; D J Greenblatt
Journal:  Clin Pharmacokinet       Date:  2000-02       Impact factor: 6.447

3.  Pharmacokinetic interaction between itraconazole and rifampin in Yucatan miniature pigs.

Authors:  G Kaltenbach; D Levêque; J D Peter; J Salmon; H Elkhaili; A Cavalier; Y Salmon; H Monteil; F Jehl
Journal:  Antimicrob Agents Chemother       Date:  1996-09       Impact factor: 5.191

Review 4.  Pharmacokinetic drug interactions with rifampicin.

Authors:  K Venkatesan
Journal:  Clin Pharmacokinet       Date:  1992-01       Impact factor: 6.447

Review 5.  Pharmacokinetic interactions with rifampicin : clinical relevance.

Authors:  Mikko Niemi; Janne T Backman; Martin F Fromm; Pertti J Neuvonen; Kari T Kivistö
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

Review 6.  Rifampin combination therapy for nonmycobacterial infections.

Authors:  Graeme N Forrest; Kimberly Tamura
Journal:  Clin Microbiol Rev       Date:  2010-01       Impact factor: 26.132

Review 7.  Adverse effects of drugs used in the management of opportunistic infections associated with HIV infection.

Authors:  B S Peters; E Carlin; R J Weston; S J Loveless; J Sweeney; J Weber; J Main
Journal:  Drug Saf       Date:  1994-06       Impact factor: 5.606

Review 8.  Pharmacokinetic drug interactions with antimicrobial agents.

Authors:  J G Gillum; D S Israel; R E Polk
Journal:  Clin Pharmacokinet       Date:  1993-12       Impact factor: 6.447

9.  Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis.

Authors:  Payam Nahid; Susan E Dorman; Narges Alipanah; Pennan M Barry; Jan L Brozek; Adithya Cattamanchi; Lelia H Chaisson; Richard E Chaisson; Charles L Daley; Malgosia Grzemska; Julie M Higashi; Christine S Ho; Philip C Hopewell; Salmaan A Keshavjee; Christian Lienhardt; Richard Menzies; Cynthia Merrifield; Masahiro Narita; Rick O'Brien; Charles A Peloquin; Ann Raftery; Jussi Saukkonen; H Simon Schaaf; Giovanni Sotgiu; Jeffrey R Starke; Giovanni Battista Migliori; Andrew Vernon
Journal:  Clin Infect Dis       Date:  2016-08-10       Impact factor: 9.079

10.  High-dose rifampicin kills persisters, shortens treatment duration, and reduces relapse rate in vitro and in vivo.

Authors:  Yanmin Hu; Alexander Liu; Fatima Ortega-Muro; Laura Alameda-Martin; Denis Mitchison; Anthony Coates
Journal:  Front Microbiol       Date:  2015-06-23       Impact factor: 5.640

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.